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increased incidence, and improved survival, following the 
management of CaP in many parts of the world.[7]
The prognosis of CaP depends on the stage at diagnosis, the 
grade of the tumor, the biological behavior of the malignant 
cells, and the modalities of treatment. In our environment 
most patients often present very late and the treatment options 
are limited; most often the management is palliative. [2- 6] The 
Introduction
Cancer of the prostate (CaP) is the most frequently diagnosed 
cancer among men in the United States.[1] Several studies have 
documented a progressive increase in the incidence of CaP 
in Nigeria and the West African sub-region in recent times, 
and different reasons have been adduced for this trend.[2-6]
The introduction of Prostate-Specific Antigen (PSA), in 
addition to Trans-Rectal Ultrasound (TRUS) and other 
circulating biomarkers, has revolutionized CaP screening, and 
these have been reported to have resulted in early detection, 
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impact of advancements in technology and molecular biology 
has not reflected in both the stage at diagnosis as well as the 
management of prostate cancer in our setting.[2-6]
We set out to survey the experience of urologists on the 
demand for prostate cancer screening in Nigeria; which we 
hope may reflect the awareness of cancer of the prostate and 
the use of technological advancement among our populace.
Materials and Methods
The setting of the study was the Annual General Meeting and 
Conference of the Nigerian Association of Urological Surgeons 
(NAUS) that took place from 26 to 29 November, 2008, at 
Kwara Hotels, Ilorin, Kwara state, Nigeria. A structured 
questionnaire was used to assess the estimated workload of 
the respondent with reference to the management of cancer 
of the prostate, the stage proportion at the time of diagnosis, 
and the proportion of patients requesting a CaP screening.
Results
Twenty-two respondents, comprising thirteen consultant 
urologists and nine specialist registrars, completed and 
returned the questionnaire and formed the basis of further 
analysis. All respondents were males, with a majority of 
them, 63.6%, in their fourth decade of life [Table 1].
Out of the consultant urologists, 10 (of 13), representing 
76.9%, were also lecturers in their respective universities. 
They were all actively practicing and a majority of them, 
76.9%, had up to 10 years experience as practicing urologists. 
Of the nine specialist registrars, five of them were half-way 
through their three-year senior residency training program.
The majority of respondents managed from 1 – 15 new 
patients with CaP per month, with 36.4% of them managing 
more than 15 new patients every month, on an average 
[Table 2]. About 95.4% of all the patients seen by the 
respondents were diagnosed at the advanced stage of 
disease, while the remaining ones were with incidental 
findings; essentially followed by prostatectomy for suspected 
benign prostate hyperplasia [Table 3].
About one-half of the respondents attended to clients 
seeking advice on CaP ‘often’ or ‘very often,’ while 40.9% 
attended to them ‘occasionally,’ with a mean of 4.67 clients 
seeking advice on CaP per month [Table 4]. A majority of 
the respondents, 20 (22), 90.9%, were ‘not aware’ of any 
national guideline on CaP screening.
Discussion
The rationale behind screening for cancer of the prostate 
(CaP), like any other cancer, is the detection of the disease 
at an early stage, when it is more likely to be curable. In 
addition to assisting in early detection, using the serum 
PSA could also predict the likelihood of CaP development 
in future.[8-10]
All the respondents, in the present survey, are actively 
practicing urologists, with a majority of them having greater 
than 10-years experience. A decade of experience in active 
practice in a region can be relied upon to give a dependable 
pattern that is representative of any disease, moreso, prevalent 
diseases like CaP. Although, it may yet be difficult to ascribe 
any objective reason for the increase in the incidence of 
CaP in our environment,[2-6] the average number of patients 
managed by the respondents per month, probably further 
affirms the already documented increase in the incidence of 
CaP.[2-4] In addition, the proportional distribution of cases at 
diagnosis agrees with the previously documented patterns,[2,3] 
with over 90% of the cases being seen at an advanced stage 
of the disease.
Table 1: The age group frequency of the respondents
Age at last birthday Frequency Percentage
31 – 40 14 63.6
41 – 50 6 27.3
51 – 60 2 9.1
Total 22 100.0
Table 2: Number of patients managed by the 
respondent for cancer of prostate per month
No. of patients Frequency Percentage
1 – 5 3 13.6
6 – 10 9 40.9
11 – 15 2 9.1
>15 8 36.4
Total 22 100.0
Table 4: The frequency of demand for advice from the 
respondents
Clients demand for advice Frequency Percentage
Very often 5 22.7
Often 6 27.3
Occasionally 9 40.9
Not usually 1 4.5
Very unusually 1 4.5
Total 22 100.0
Table 3: The stage-at-diagnosis of cancer prostate by 
the respondents
Stage at diagnosis Frequency Percentage
Incidental finding 1 4.5
Localized disease - -
Locally advanced 14 63.6
Metastatic diseases 7 31.8
Total 22 100.0
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Despite the adoption of screening for CaP in many 
parts of Europe and America, there still exist significant 
controversies; however, there was consensus of opinion that 
screening for CaP was beneficial. An incidence of 127 cases 
per 100,000 population has been documented in Nigeria;[2] 
this is comparable with other parts of the western world and 
thus screening of the population is paramount. Basically, the 
screening for CaP involves identifying the at-risk individual 
and performing one or all of the following procedures in 
them: A digital rectal examination (DRE), TRUS of the 
prostate, and serum PSA estimation.[8] A sextant prostate 
biopsy for histological appraisal is performed when indicated, 
for the final diagnosis.
The use of DRE was found to have an estimated cancer 
detection rate of one to two percent when used as a primary 
detection method in a study.[11] Furthermore, among those 
with detectable cancer using DRE, 48 – 85% already had an 
extraprostatic disease at the time of diagnosis; in addition 
to this, some men were not comfortable with DRE because 
they were embarrassed or fearful that the procedure may 
be painful.[12] The implication of the foregoing is that DRE 
alone cannot be readily relied upon for screening. To add 
to this, the inherent experience of examining a hard and 
nodular prostate of advanced disease in our setting may 
affect our experience with identifying a lesion of localized 
disease that is amenable to cure.
In a study in which the three modalities were combined, it was 
shown that DRE alone and TRUS alone would have missed 
32 and 43% of CaP, respectively.[13] In the same study, serum 
PSA was found to detect CaP more accurately than DRE or 
TRUS and of the two-test combinations, serum PSA plus 
DRE had the highest sensitivity and specificity rates.[13] Based 
on the foregoing discussion and with limited availability of 
TRUS facility in many of our centers, it was very clear that 
serum PSA estimation would occupy a vital role in screening 
for CaP in our sub-region, like many places in the world.
In Nigeria, the availability of PSA testing was limited to 
about two decades ago, thus the diagnosis of CaP was based 
on DRE, serum estimation of the total, and prostatic acid 
phosphatase and needle biopsy.[2] At present there is free 
accessibility to different assay kits for the estimation of PSA in 
Nigeria, however, these have not had a significant impact on 
the stage-at-diagnosis of CaP as predicted by Osegbe et al.[2]
The forecast by Osegbe et al.,[2] with regard to the influence 
that serum PSA would have on the incidence and stage-shift 
at diagnosis, will be difficult to achieve in Nigeria in the 
near future. There is still no documented national guideline 
on CaP screening, as attested to by a majority (90.9%) of 
the respondents. This means that a nationally coordinated 
program of enlightening the populace to the menace of 
CaP is not in existence and this probably accounts for the 
reason why almost one-half of the urologists attend to clients 
demanding for screening for CaP ‘occasionally’; with a mean 
of 4.69 clients seeking advice per month.
There was evidence of an increasing incidence of cancer of 
the prostate with the majority still presenting at late stages 
of the disease. Despite the availability of PSA, the mean 
number of patients presenting for screening for CaP was still 
low. It is the authors’ belief that the trend may not change 
until there is an appropriate effort at health education, to 
enlighten the populace.
In conclusion, the response from the practitioner seems 
to suggest a continuous increase in the incidence of CaP; 
and a majority of the cases still present in an advanced 
stage. There is a remarkable unawareness on the part of 
the populace to present for screening, which may not be 
unconnected with the absence of a national guideline on 
screening for CaP. The Nigerian Association of Urological 
Surgeons will have a prominent role to play in this advocacy.
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